Yang Xia, founder and chairwoman of Jinbo Biology, shows models of recombined human-origin collagen to staff members during a company training session.WU LIUHONG/FOR CHINA DAILY
As one of the 14 strategic emerging industries in Shanxi province, the biomedicine sector is showing great potential for growth thanks to improved innovation capabilities among local players.
Among many new medicine releases into the market, the recombined human-origin collagen III developed by Taiyuan-based Jinbo Biology is among the most remarkable because of its globally advanced level.
Yang Xia, founder and board chairwoman of Jinbo Biology, said the company is the only enterprise in the world that mass produces the medicine. Its volume production began in January.
"Unlike other industries, the research and development of new medicines needs more time-at least 10 years," Yang said. "This requires a company to consistently invest in R&D and continuously improve its innovative strength."
However, even with huge amounts of investment and a time-consuming process, the success rate of new medicine development is only about 10 percent, Yang said.
"In the R&D of recombined human-origin collagen III, we made our breakthrough in the lab after numerous failures over more than 1,000 days," Yang said. "It takes a couple of years to commercialize the lab results and another couple of years to realize mass production."
For the commercialization of the new medicine, Jinbo Biology has invested about 250 million yuan ($38.6 million) in building a technology transfer center.
"With this center in place, we can develop medicine varieties that can be applied to different scenarios ranging from surgery, gynecology and dermatology to skin care cosmetics," Yang explained.
Despite the huge investment and uncertainties in the long R&D period, Yang said she is still optimistic about the biomedicine industry in Shanxi because the market environment is friendly thanks to strong support from the government.
"Innovative industries like biomedicine are prioritized in China and the State has recently issued a number of preferential policies for them," said Ma Jingbo, an official at the Shanxi Department of Industry and Information Technology.
He noted that Shanxi has offered further incentives for such industries.
For instance, the Shanxi Department of Industry and Information Technology has set aside a special fund to award companies with strong investment in R&D.
"Companies with more than 20 percent growth in annual R&D investment are eligible for awards from the fund," Ma explained, adding that biomedicine companies with constant growth in R&D investment are the major beneficiaries of such a policy.
Other supportive measures from the local government include promoting collaborations between enterprises and research institutions, encouraging the sharing of public R&D facilities and labs, protecting intellectual property rights, and helping enterprises recruit and foster R&D professionals.
"The protection of IPR is of great significance for high-tech companies like Jinbo Biology," Yang said.
Jinbo Biology is the holder of 23 invention patents, including two international patents. The company has been recognized as a State-level high-tech enterprise for four consecutive years, according to Yang.
Wang Pei contributed to this story.
By YUAN SHENGGAO
山西路桥:党建引领 建好“四好农村路”山西路桥建设集团党委扎实开展“党建质量提升年”,实施“六大工程”,立足“十四五”高质量、高速度、高效益发展的战略基点,全面提高党建质量和党建引领发展水平,为打造“国内一流的交通基础设施投资、建设、施工现代化企业集团”提供坚强政治保障。
常住人口3491万 山西人口普查数据"出炉"山西省统计局向社会通报山西省第七次全国人口普查主要数据。数据显示,山西省常住人口为34915616人,比2010年(第六次全国人口普查数据,下同)减少2.23%,年平均减少0.23%。山西省常住人口总量减少,主要受人口流动变化等因素影响。